Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia (Q33379934)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia |
scientific article |
Statements
1 reference
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia (English)
1 reference
Hagop M Kantarjian
1 reference
Neil P Shah
1 reference
Dong-Wook Kim
1 reference
Pedro E Dorlhiac-Llacer
1 reference
Jorge H Milone
1 reference
Jorge Vela-Ojeda
1 reference
Richard T Silver
1 reference
H Jean Khoury
1 reference
Aude Charbonnier
1 reference
Nina Khoroshko
1 reference
Ronald L Paquette
1 reference
Michael Deininger
1 reference
Robert H Collins
1 reference
Irma Otero
1 reference
Eric Bleickardt
1 reference
Lewis Strauss
1 reference
Stephen Francis
1 reference
9 June 2008
1 reference
1 reference
26
1 reference
19
1 reference
3204-3212
1 reference
Identifiers
1 reference
1 reference